GRIFOLS’ PLASMA WORTH A SHOT (BUY; 27% UPSIDE)
17/09/20 -"Since our last Teaser in May 2019, it has been a rollercoaster ride for Grifols (Buy, Spain), a leading player in the $23bn oligopolistic plasma marketplace. While the FDA approval for the ..."
Pages
56
Language
English
Published on
17/09/20
You may also be interested by these reports :
24/09/26
A years/decades long search for revolutionary multi-blockbuster drug(s), a phenomenal run for some years and then concerns sprout around ...
21/09/26
Novo’s CMD announcements, including the diversification plan and a vague mid-term sales target, disappointed investors. Against the backdrop of ...
21/09/26
Siegfried’s (Buy, Switzerland) post-Covid success story has been nipped in the bud by three years of low-single-digit (LSD) growth (in CHF). ...
17/09/26
Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen’s near- and mid-term risks. ...